No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Spinal Elements Reports Expansion of MIS Ultra™ Offering with the Full Market Release of the Lucent® XP Wide Expandable Device for MIS TLIF

Editor: What To Know

  • The company's line of expandable devices has shown rapid adoption and growth over the past year, and the company plans on further line additions to the Lucent XP offering, as well as other expandable interbody technologies to complement the MIS Ultra platform.
  • The Lucent XP Wide System is an interbody device with an anatomically oriented lordotic design that can expand in height and increase in lordosis after implantation.
  • The system also allows me to place a large TLIF cage in a narrow corridor in patients with a collapsed disc without disruption of the exiting nerve root.

Spinal Elements, a spine technology company, today announced the newest introduction in its MIS Ultra™ suite of products with the full release of the Lucent® XP Wide expandable interbody device. This addition to Spinal Elements’ expandable interbody portfolio offers surgeons a wider footprint option than previously available and is designed with an anatomically oriented lordotic angle.

Spinal Elements notes the system is optimized to be used in MIS TLIF (transforaminal lumbar interbody fusion) procedures, but can also be used in open TLIF procedures.

With this expanded commercial release, Spinal Elements adds to the increasing number of procedural solutions within their MIS Ultra platform of products. The company’s line of expandable devices has shown rapid adoption and growth over the past year, and the company plans on further line additions to the Lucent XP offering, as well as other expandable interbody technologies to complement the MIS Ultra platform.

The Lucent XP Wide System is an interbody device with an anatomically oriented lordotic design that can expand in height and increase in lordosis after implantation. The height expansion helps restore the height of the disc space, while the lordotic angle helps correct the natural curvature of the spine. With the Lucent XP Wide device, surgeons can achieve up to 15 degrees of lordotic angle, while helping to improve spinal stability and alignment.

In addition, the Lucent XP Wide system is the only available expandable device that it is made primarily of polyetheretherketone (PEEK) and features Spinal Elements’ Ti-Bond® porous titanium coating. Ti-Bond is a hydrophilic porous titanium coating with nano-scale surface features that has been used in tens of thousands of Spinal Elements fusion procedures dating back to 2012.

Orthopedic Spine Surgeon and designer, Paul Kim, MD of the Spine Institute of San Diego, CA, says of the Lucent XP Wide System: “With oblique lordosis in the design, I am able to achieve expansion and lordosis in the midline, instead of asymmetrical lordosis. The system also allows me to place a large TLIF cage in a narrow corridor in patients with a collapsed disc without disruption of the exiting nerve root. I am a big believer in MIS TLIF and this system addresses some of the challenges that can be seen in these surgeries.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy